Compare Crispr Therapeutics AG (CRSP) vs Lumen Technologies Inc (LUMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Lumen Technologies Inc — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Lumen Technologies Inc trades at $5.28 (market cap $5.73B). The key difference: Lumen Technologies Inc is the larger of the two by market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Lumen Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Lumen Technologies Inc for 40 Days on average.
| CRSP | LUMN | |
|---|---|---|
Market Cap | $4.88B | $5.73B |
Volume | 2,861,747 | 17,079,799 |
Sector | Health | Media |
52-Week High | $74.92 | $11.83 |
52-Week Low | $44.34 | $5.53 |
Typical Hold Time | 77 Days | 40 Days |
Enterprise Value | $3.30B | $17.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
LUMN trades at $5.56, down 5.92% on the day, reflecting ongoing investor caution amid weak profitability and high debt. The stock shows a bearish technical trend with key support at $5.00, while fundamentals reveal declining revenue, negative net income margins, and a challenging turnaround effort. Recent news highlights a Nasdaq listing move and AI-focused networking initiatives, but legacy telecom declines persist.
Outlook remains speculative with high execution risk; the company's deep value (P/S 0.47) and AI growth potential contrast with consistent losses and substantial leverage. Analyst consensus is Reduce, with 60.7% Hold ratings, signaling limited near-term confidence despite strategic pivots.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →
